|
Monday 2 March 2009, 09.00 - 18.30 UK Trade & Investment is bringing together more than 100 leading British and Nordic oncology companies and organisations at the UK-Nordic Oncology Conference. Join keynote speakers from AstraZeneca, GlaxoSmithKline, CRT, Ark Therapeutics and the Danish Cancer Centre, jointly chaired by Dr John Hood, Vice Chancellor, University of Oxford, and Prof Jesper Zeuthen, together with speakers from 12 of the best Nordic biotechnology companies in the oncology field Recognising the significant demand for strategic and effective business alliances and collaboration to enhance oncology research, clinical development and commercial potential, the core aim of the conference is to:
The UK-Nordic Oncology Conference is free to attend and is an excellent platform for your organisation to gain high-level access to valuable partner prospects, inspirational high-profile keynote speakers and Nordic oncology pipeline showcases. Use this occasion for unmatched networking with peers and colleagues from the UK-Nordic oncology community. - Download a flyer to advertise the event to colleagues - Find out more about exhibiting your company at the event To find out more about the Conference, please contact the organisers by emailing uknordiconcology@fco.gov.uk,or call +45 35 44 52 81 |
What the conference speakers are saying: "AstraZeneca has a strong heritage in oncology spanning more than 30 years of discovering and developing innovative medicines. Throughout our history, we have always placed great value on maintaining strong alliances with leading academic centers of excellence, biotech, pharmaceutical companies and other collaborators. Targeted partnering conferences such as this, provide an important forum to meet and talk with potential partners who share our commitment for discovering and developing new therapeutics which can hopefully make a meaningful difference for patients confronting cancer." At GSK our vision is to constantly strive to improve the quality of life for people throughout the world - it is the cornerstone of everything we do. In oncology, we are at the forefront of the 'bench to bedside' approach, transforming the way that cancer treatments are discovered and developed, resulting in one of the most robust pipelines in the oncology sector.
|
ENABLING STRATEGIC ONCOLOGY ALLIANCES
